Vitrolife

Vitrolife Group is a Gothenburg, Sweden-based global medical device and genetic testing company founded in 1994, dedicated exclusively to the reproductive-health sector. The company develops, manufactures, and distributes products that support every stage of the IVF journey, from gamete handling and embryo culture to cryopreservation and error prevention. Its flagship EmbryoScope+ time-lapse system, backed by over 15 years of development, is widely used by IVF clinics to improve embryo culture and evaluation.

In 2021, Vitrolife significantly expanded its capabilities by acquiring Igenomix, a reproductive genetic testing services leader founded in 2011, enabling the group to offer clinics and patients comprehensive support across the full fertility journey. The company has completed seven acquisitions in total and is active across major markets including the United States, Australia, China, Japan, France, Italy, and the United Kingdom.

Vitrolife AB (publ) is listed on NASDAQ Stockholm Large Cap under the ticker VITR and has been publicly traded since 2001. It employs approximately 1,084 people, generates trailing twelve-month revenue of roughly $361 million, and carries a market capitalisation of approximately $1.39 billion. Its 25-plus years of focused innovation in IVF technology make it a central player in the global assisted reproduction industry.

For companies innovating in fertility technology, embryology AI, reproductive genomics, or IVF lab instrumentation, Vitrolife represents a strategically important partner, customer, or benchmark given its dominant market position and end-to-end portfolio across the reproductive-health value chain.